Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...

Law Offices of Howard G. Smith reminds investors of the upcoming August 25, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Hims & Hers Health, Inc ...

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

Protagonist Therapeutics is taking aim directly at Eli Lilly's obesity treatment with a newly announced drug that uses the same mechanism.

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded ...

Novo Nordisk A/S and Eli Lilly & Co ... ramp up next year when cheaper alternative versions of semaglutide — the active ingredient in Novo’s Wegovy — launch after semaglutide’s China patent expires.

The weight loss and diabetes drug Wegovy (also known as Ozempic) which is only available on prescription, should be on pharmacy shelves as of 1 July, drug maker Novo Nordisk confirmed. It ends a years ...